SciSparc: Subsidiary NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
SciSparc's subsidiary NeuroThera Labs has launched a Phase IIb clinical trial for its drug candidate SCI-110 at the Yale Child Study Center for the treatment of Tourette Syndrome in adults. The randomized, double-blind trial builds on Phase IIa data that showed a 21% average reduction in tics, with primary endpoints measuring severity changes at weeks 12 and 26.
Key figures
- Drug Name
- SCI-110
- Phase Of Trial
- Phase IIb
- Patient age range
- 18-65
- Phase IIa tic reduction
- 21%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.